The country's leading drug makers, including Ranbaxy Laboratories, Cipla, Cadila Pharmaceuticals, Nicholas Piramal and Wockhardt, will soon withdraw about 60 drug combinations from the market. The voluntary move comes a little more than a year after the Central Drugs Standard Control Organisation (CDSCO), the central authority that approves new drugs for marketing, had asked the drug makers to withdraw the ‘combination drugs' as they are "unnecessary" and may pose health hazards. The Drugs Controller General of India (DCGI) had banned 294 combination drugs sold under nearly 1,053 brand names from the market in June 2007. Since then, the pharma industry and the the drug authority have been locked in a legal battle.
Monday, July 7, 2008
Subscribe to:
Post Comments (Atom)
DISCLAIMER
DISCLAIMER: INVESTING AND TRADING IS VERY RISKY AND FINANCIAL LOSSES ARE OFTEN THE RESULT.
Investment success is far from a sure thing. This site is solely intended for educational purposes. I am not a registered investment advisor and it is not my intention to provide anyone with investment advice. I am not recommending that any reader of this blog buy, sell, short, or engage in any other investment strategy based upon the content set forth herein. I strongly urge all readers to perform their own due diligence before investing and or trading their funds. I will not be responsible for any readers financial losses.
0 comments:
Post a Comment